Eversept Partners LP Cuts Stock Position in Repligen Co. (NASDAQ:RGEN)

Eversept Partners LP reduced its position in Repligen Co. (NASDAQ:RGEN) by 67.0% during the fourth quarter, Holdings Channel reports. The institutional investor owned 54,066 shares of the biotechnology company’s stock after selling 109,527 shares during the quarter. Repligen comprises 0.7% of Eversept Partners LP’s investment portfolio, making the stock its 27th largest holding. Eversept Partners LP’s holdings in Repligen were worth $7,782,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Ballentine Partners LLC increased its position in shares of Repligen by 4.0% during the fourth quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company’s stock worth $270,000 after purchasing an additional 72 shares in the last quarter. CIBC Asset Management Inc grew its stake in shares of Repligen by 5.0% during the fourth quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company’s stock worth $246,000 after acquiring an additional 81 shares during the last quarter. MML Investors Services LLC increased its stake in Repligen by 2.7% during the 3rd quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock valued at $503,000 after purchasing an additional 89 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Repligen by 15.2% during the fourth quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock worth $98,000 after purchasing an additional 90 shares during the period. Finally, Louisiana State Employees Retirement System raised its holdings in shares of Repligen by 0.7% during the fourth quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company’s stock worth $2,087,000 after purchasing an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on RGEN. StockNews.com downgraded Repligen from a “hold” rating to a “sell” rating in a research report on Thursday, April 17th. Evercore ISI began coverage on Repligen in a report on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 price target for the company. Royal Bank of Canada lifted their target price on shares of Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a report on Friday, February 21st. TD Cowen assumed coverage on shares of Repligen in a research note on Monday, February 10th. They set a “buy” rating and a $200.00 target price on the stock. Finally, Canaccord Genuity Group lowered their price target on Repligen from $170.00 to $150.00 and set a “hold” rating on the stock in a research report on Wednesday, April 16th. One analyst has rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, Repligen presently has an average rating of “Hold” and an average price target of $176.82.

Repligen Trading Up 1.3 %

NASDAQ RGEN opened at $131.64 on Tuesday. Repligen Co. has a 12 month low of $102.97 and a 12 month high of $182.52. The stock has a market capitalization of $7.39 billion, a P/E ratio of -258.12, a PEG ratio of 4.54 and a beta of 1.27. The firm’s 50-day moving average is $140.09 and its two-hundred day moving average is $145.74. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.03. The firm had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. On average, sell-side analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current year.

Insider Activity

In other news, Director Margaret Pax bought 250 shares of Repligen stock in a transaction that occurred on Monday, March 17th. The shares were purchased at an average price of $150.69 per share, with a total value of $37,672.50. Following the completion of the acquisition, the director now directly owns 1,043 shares in the company, valued at $157,169.67. The trade was a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.